Massive study reveals COVID-19's toll on work and wages
NCT ID NCT07072793
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at over 131,000 high-risk COVID-19 patients in the US to understand how the illness affected their ability to work and the associated costs. Researchers compared those who took the antiviral Paxlovid with those who did not, using insurance claims data from 2021-2022. The goal was to measure missed work days, disability claims, and related expenses, providing insights for employers and public health planning.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- nirmatrelvir-ritonavir (Paxlovid)
- What this could lead to
- If successful, this study could help employers and policymakers understand the economic impact of COVID-19 and the value of antiviral treatments in reducing work loss.
- What could go wrong
- This is an observational study using insurance claims data, so it cannot prove cause and effect. Results may not apply to all populations or reflect real-world work loss accurately.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
131,005 people
The number who actually took part.
- Started
-
Oct 2024
- Finished
-
Nov 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
retrospective cohort study of adult, high-risk patients diagnosed with COVID-19 using data from the Merative™ MarketScan® Commercial, Medicare, and Health and Productivity Management (HPM) Databases. The index date for both cohorts will be the date of the first COVID-19 diagnosis and patients will be followed over a 6-month pre-period and variable post-period. The post-period will be a minimum of 30 days to allow patients the opportunity to experience the primary study outcomes of work loss days (absence, STD, and LTD) along with associated indirect costs.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * \>1 non-diagnostic2 outpatient medical claim in the MarketScan Commercial or Medicare Database with the International Classification of Diseases, 10th Revision (ICD-10) diagnosis code for COVID-19 (U071) between December 16, 2021 (5 days prior to the date of emergency use authorization of NMV/r) and December 1, 2022 (30 days prior to the end of available HPM data); the date of the earliest qualifying claim is the index date. * Primary beneficiary on their insurance policy (i.e., eligible for inclusion in the MarketScan HPM Database) * \>6 months of continuous enrollment with medical and pharmacy benefits in the MarketScan Commercial or Medicare Database before the index date (baseline period) * \>30 days of continuous enrollment with medical and pharmacy benefits in the MarketScan Commercial or Medicare Database after and including the index date (minimum follow-up period) * Treated cohort ONLY: ≥1 claim for Paxlovid within 5 days of index (index date and next 4 days) Exclusion Criteria: * Evidence of death on the index date or the following day * Any inpatient admission on the index date or the following day * ≥1 inpatient claim with a COVID-19 diagnosis in any position on the claim during the 30 days before the index date * \>1 non-diagnostic claim with a diagnosis code for stage 4 or stage 5 chronic kidney disease, end stage renal disease, or a procedure code for dialysis, during the baseline period or on the index date
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 (coronavirus disease 2019) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer New York
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.